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1. Introduction 
1.1 Cancer Incidents 
According to the Norwegian Cancer Registry, 26 121 new cases of cancer were 
recorded in Norway in 2008, of which 14 000 occurred in men and 12 121 in women. 
Cancers of the prostate, female breast, colon and lung are the most common cancers 
and comprise almost half of the total cancer incidents. Breast cancer remains the most 
frequent neoplasm in women, with 2 753 new cases in Norway in 2008 [1]. 
Fortunately, the introduction and improvement of breast cancer screening, together 
with better treatment, have reduced breast cancer mortality in western countries [2, 
3]. Nevertheless, breast cancer still remains the leading cause of cancer mortality in 
women worldwide [4], with over 400 000 deaths per year, and further improvement 
of both detection and therapy is desirable and necessary.  
Genetic factors, including the major susceptibility genes (BRCA1, BRCA2), may 
account for up to 10% of breast cancer cases in developed countries. However, the 
major factors influencing breast cancer risk are obesity, alcohol, exogenous hormones 
(oral contraceptives, hormone replacement therapy) and, possibly diet and lack of 
physical activity [4].  
1.2 Tumor Biology 
The word tumor is derived from the Latin word meaning “swelling”, and is a lesion 
formed by abnormal growth of cells. Tumor is, however, not synonymous with 
cancer and can be both benign and malign. Nevertheless, for the remaining part of 
this thesis, malignant tumors are referred to as tumors. Cancer is a group of diseases 
characterized by unregulated cell growth and the invasion and spread of cells from 
the site of origin to other sites in the body [5]. Cancers can grow in cell suspension 
(e.g. leukemia), but most grow as solid masses of tissue. The complexity of these 
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diseases has been, and still is, one of the biggest challenges for clinicians and cancer 
researchers. The complexity lies not only in the fact that there are different types of 
cancers, but within each type of cancer there is a great variation in both behaviour 
and responses to treatment.  
1.2.1 Hallmarks of Cancer 
Hanahan and Weinberg [6] suggested six molecular, biochemical and cellular traits 
that characterize the development and progression of malignant tumors, and called 
them jointly as “The six hallmarks of cancer”. Through different mechanisms, this set 
of functional capabilities is acquired during the development of the cancers. 
The six hallmarks are [6]: 
1. Growth signal autonomy 
Oncogenes mimicking normal growth signalling and growth signals from the 
stromal cells make the cancer cells independent on external growth factor 
signalling to proliferate.  
2. Insensitivity to growth inhibitory signals 
The main example is disruption of the retinoblastoma protein (pRB)-pathway 
in cancer cells liberates the E2F transcription factors and allows cell 
proliferation, even with anti-proliferative signalling. 
3. Evasion of apoptosis 
Many changes can lead to acquisition of apoptotic resistance, but mutation in 
the tumor suppressor gene p53 is the most common one. Functional 
inactivation of the p53 protein destroys the DNA damage sensor that normally 
induces the apoptotic cascade, opening for maintenance of mutations. 
4. Unlimited replicative potential 
Telomerase maintains the length of the chromosomes, the telomeres, making 
cancer cells avoid entering senescence and giving them an unlimited 
replicative potential. 
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5. Angiogenesis 
To be able to survive and grow, the cancer cells are dependent on formation 
of new blood vessels, angiogenesis. Alteration of the balance between 
angiogenic inducers and inhibitors can activate the ‘angiogenic switch’. 
6. Invasion and metastasis 
Normal cells maintain their location in the body, and generally do not 
migrate. Successful migration and invasion depend on alteration of the 
binding of cells to their surroundings, like changes in cell adhesion molecules 
(CAMs), and are also dependent on the capabilities of all the previously 
mentioned hallmarks. Migration and invasion of cancer cells to other parts of 
the body is the major cause of cancer deaths. 
 
From the above, it is evident that it is important not to study tumor cells in isolation, 
but rather in a context of surrounding and infiltrating tissue; collectively known as the 
tumor stroma or the tumor microenvironment.  
1.2.2 The Tumor Microenvironment 
The solid tumor forms a highly complex tissue, comprising heterogeneous malignant 
cells, as well as normal- and cancer-associated fibroblasts (CAFs), immune cells, 
pericytes, endothelial cells and extracellular matrix (ECM) (Figure 1)  [7].  
In general, the tumor stroma is characterized by low proteoglycan and hyaluronan 
concentrations and absence of an anatomically well-defined lymphatic network [8]. 
Additionally, the structural network of a tumor contains a dense network of collagen 
fibres, which are thicker and more numerous than that of normal connective tissue, 
and results in a more rigid tumor tissue [8]. Cancer-associated fibroblasts, 
inflammatory cells and mediators infiltrate the tumor stroma. Together they secrete 
various cytokines, growth factors and hormones than can directly stimulate tumor cell 
proliferation, survival, angiogenesis, invasion and metastasis [7, 9, 10].  
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Figure 1: Anatomy of normal tissue (left panel) and tumor tissue (right panel). Tumor blood 
vessels are disorganized, tortuous and dilated, with uneven diameter and excessive 
branching and shunts, leading to inefficient blood flow. Furthermore, tumors contain a great 
number of infiltrating cancer-associated fibroblasts and inflammatory cells, in addition to 
the neoplasic tumor cells. The collagen network of solid tumors is more rigid than that of 
normal tissue and there is absence of an anatomically well defined lymphatic network. 
Adapted from Heldin et al. [11], with permission from Nature Publishing Group. 
 
Tumors can not grow beyond a critical size or metastasize to other organs without 
blood vessels. Angiogenesis provides a principle mechanism for the maintenance of 
adequate blood flow in an expanding tumor tissue. Due to an imbalance in the 
angiogenic regulators, tumors have highly disorganized, tortuous and dilated blood 
vessels, with uneven diameter and excessive branching and shunts [12], leading to a 
highly variable blood flow. Together, these traits lead to inefficient and incomplete 
supply of nutrients and removal of waste products, and a hypoxic tumor 
microenvironment. Blood flow within a tumor is anything but uniform. Tumors 
contain both highly perfused areas, which are rapidly growing, and areas with 
reduced blood flow, which often are associated with development of necrosis [13]. In 
essence, the abnormal vasculature of tumors, result in an abnormal 
microenvironment, and together they form an obstacle to the delivery and efficacy of 
cancer therapy.  
During cancer progression, genetically transformed cells (cancer cells) change the 
stromal host compartment, to form a permissive and supportive microenvironment for 
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further growth and progression [14]. Thus, it is now appreciated that the tumor 
microenvironment is crucial for cancer initiation, growth and progression, and that 
the interaction between the stromal components and the tumor cells is bidirectional 
[7, 15, 16].  
1.2.3 Transcapillary Exchange 
Transport of fluid and solute molecules in the interstitium, i.e. the extracellular fluid 
compartment between blood vessels and cells, is governed by the biological and 
physiochemical properties of the molecule and the properties of the ECM [8], and is 
an important feature influencing the tumors response to therapy. Transport of 
materials across the vessel wall is mainly governed by diffusion, i.e. solute transfer 
driven by a concentration gradient, as summarized in Fick`s law: 
 xCDAJ S  /  
Formula 1: Fick`s law
Js= The mass of solute transferred by diffusion per unit time, 
 C= The concentration difference across the capillary wall,  
x= Distance (Thickness of the capillary wall), A= Surface area, 
 D= The diffusion coefficient (inversely related to solute size). 
 
However, convection, i.e. solute flux carried by the fluid flux, also contributes to 
transvascular transport of materials. Transcapillary fluid balance aims to maintain 
constant fluid volume in the interstitium. The balance is determined by: 1) The 
properties of the capillary membrane, 2) The transcapillary hydrostatic pressure, 3) 
The transcapillary colloid osmotic pressure. 
E. H. Starling described the relationship between these factors in 1896, and thus the 
factors influencing the transcapillary fluid flux are often referred to as the Starling 
equation [17]: 
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Formula 2: The Starling equation.
Jv= Filtration, CFC= Capillary filtration coefficient, Pc= Capillary hydrostatic pressure, 
Pif= Interstitial fluid pressure, = The colloid osmotic reflection coefficient, 
COPc= Colloid osmotic pressure (capillary), COPif= Colloid osmotic pressure (interstitium) 
 
The CFC is determined by the surface area of the capillary wall and its hydraulic 
conductivity.  is the colloid osmotic reflection coefficient for proteins. The primary 
driving force for filtration is the capillary hydrostatic pressure (Pc). Filtration is on the 
other hand opposed by the colloid osmotic pressure of the plasma proteins (COPc), 
which tends to hold the fluid in the circulation. COPif is the colloid osmotic pressure 
tending to pull fluid out of the circulation. The interstitial fluid pressure (Pif) is the 
pressure exerted by the interstitium, which in skin normally varies between 0 and -2 
mmHg [18]. This pressure is crucial in the control of a stable volume in the 
interstitium and is mainly determined by the capillary fluid filtration and the lymph 
flow, in other words the extracellular fluid volume. In addition, the forces governed 
by the structural network of the interstitium are a contributing factor in regulation of 
Pif, as determined by the interstitial pressure-volume relationship; the compliance 
[19]. It is now well established that Pif in most solid tumors is increased (up to 
~60mmHg) [11]. An increase in Pif counteracts filtration, and has therefore been 
proposed as an obstacle to cancer therapy [11]. In Paper II we have studied the 
influence of Pif on the uptake of chemotherapy in the DMBA (dimetyl--
benzanthracene)-induced mammary tumor model. 
The mentioned features of the tumor biology influence growth and development of 
tumors, and its susceptibility to therapy. Furthermore, tumor hypoxia is an important 
factor, shared by most solid tumors, which will be thoroughly elucidated further in 
this thesis. 
 15
1.3 Tumor hypoxia 
Hypoxia is defined as a reduction in the normal level of tissue oxygen. Tumor growth 
often overrides the ability of the tumor vasculature to adapt to the increasing oxygen 
demand. In addition, as already stated, tumor vasculature constitutes a fundamental 
difference between normal and tumor tissue, with its structural and functional 
abnormalities. Together, this often leads to solid tumors with areas subjected to acute 
or chronic hypoxia [20]. Although severe or prolonged hypoxia is toxic to both 
cancer cells and normal cells, adaptation to the hypoxic microenvironment has 
allowed cancer cells to survive and proliferate in this hostile milieu [21].  
Traditionally, studies of tumor hypoxia were performed because of its proven effect 
on resistance to radiation therapy [22]. Later, Hockel et al. [23] showed that low 
oxygen tension in tumors was also associated with increased metastasis and poor 
survival rate. Michieli et al. [20]  stated that the insufficient oxygen supply can limit 
tumor cell division, but on the other hand it can also select for more malignant cells 
and thereby lead to tumor progression. This “Darwinian selection” will lead to more 
aggressive cancer cells [20].  
Hypoxia is known to result in cellular responses which improves oxygenation and 
viability through induction of angiogenesis, a raise in energy production by increased 
glycolytic metabolism and up-regulation of genes involved in cell survival/apoptosis 
(Figure 2) [24]. Hypoxia has also been shown to increase the genetic instability, 
activate invasive growth and persevere the undifferentiated cell state, which all in 
turn can be advantageous during tumor progression [20, 21].  
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Figure 2: Tumors survive and progress under hypoxic conditions due to adaptations of 
cellular responses which improve oxygenation and viability through induction of 
angiogenesis, increase in glycolytic metabolism and up-regulation of genes involved in cell 
survival/apoptosis, leading to more aggressive and metastatic tumors. Hypoxia is also 
known to induce resistance to therapy. EMT: Epithelial-to-Mesenchymal transition, HIF-1: 
Hypoxia inducible factor 1, ROS: Reactive oxygen species. 
 
1.3.1 Hypoxia and the Angiogenic Switch 
The `angiogenic switch` involves up-regulation of pro-angiogenic factors and down-
regulation of anti-angiogenic factors, causing formation of new blood vessels, 
although with variable degree of functionality. Generally, tumors cannot grow 
beyond ~ 1 mm in diameter without being supplied by new blood vessels [25]. 
Hypoxia is the most potent stimulator of angiogenesis. It is somehow paradoxical that 
the tumor tissue is hypoxic due to abnormal and non-functional tumor vasculature, as 
the hypoxic tumor tissue is responsible for inducing angiogenesis in the first place 
[26].  
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The hypoxia-inducible factor 1 (HIF-1)-pathway is one way that cells respond to 
reduced oxygen levels. HIF-1 is a transcription factor composed of HIF-1 and HIF-
1/aryl hydrocarbon receptor nuclear translocator (ARNT) [27, 28]. The -subunit is 
constitutively expressed, whereas the stability and activity of the -subunit is 
inducible. The availability of the HIF-1-subunit is primarily regulated by cellular 
oxygen levels [29], but also by growth factors [30]. Thus, in presence of oxygen, 
HIF-1 is bound to the tumor suppressor Von Hippel-Lindau (VHL) protein, causing 
ubiquitylation and degradation by the proteasome. In absence of oxygen, however, 
HIF-1 translocates to the nucleus, where it dimerizes with ARNT, binds to hypoxia-
response elements (HRE’s), and thereby activates the transcription of several 
hypoxia-response genes. Pro-angiogenic growth factors, like transforming growth 
factor- (TGF-), platelet-derived growth factor (PDGF), vascular endothelial growth 
factor (VEGF) are all induced by HIF-1, stimulating angiogenesis. 
1.3.2 Hypoxia and Cell Survival 
Normally, when mutations occur and DNA repair enzymes cannot correct the error, 
the apoptotic cascade is activated, leading to programmed cell death. However, the 
escape from this apoptotic program is one of the hallmarks of cancer, and tumor cells 
thereby maintain uncorrected mutations. The p53 tumor suppressor gene has been 
described as “the guardian of the genome”, and can activate DNA repair enzymes, 
induce growth arrest and initiate apoptosis, and thereby protect cells against 
neoplastic transformation. Hypoxia is, in addition to DNA damage, able to stimulate 
p53 levels and activate the p53 protein [31]. However, deregulation and loss of 
function of p53 is seen in more than 50% of human cancers [31], and has proved to 
promote growth and malignant progression. Telomere length is an important factor 
deciding cell replicating ability, activation of p53 lead the cells into senescence when 
the telomeres have eroded. However, hypoxia has been shown to reduced telomere 
erosion by activation of telomerase, resulting in unlimited replicative potential [32]. 
Furthermore, Graeber et al. [33] showed that p53 mutation results in over-expression 
of the apoptotic inhibitor Bcl-2 and thus results in a substantial reduction of hypoxia-
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induced cell death. Hypoxia thereby acts as a physiological selective agent, 
promoting the clonal expansion of apoptosis-resistant cells [33]. 
Additionally, Ravi et al. [34] showed that loss of p53 function in tumor cells 
enhances HIF-1 levels and increases the transcription of pro-angiogenic genes like 
VEGF in response to hypoxia. 
1.3.3 Hypoxia and the Glycolytic Switch 
Insufficient oxygen availability in tumors causes a shift in energy production from 
oxidative phosphorylation to anaerobic glycolysis to satisfy the tumor`s energy 
demand. Further, adaption to intermittent hypoxia leads to persistent metabolism of 
glucose to lactate even during aerobic conditions, a process called “the Warburg 
effect” [35]. Glycolysis leads to a lower ATP yield than oxidative phosphorylation, 
and thereby forces the tumors to increase their metabolic rate [13, 36]. Important 
components of the glycolytic pathways are the glucose transporters GLUT-1 and 
GLUT-3 and the enzyme hexokinase, all genes regulated by HIF-1, and thus by 
hypoxia [36]. It has also been showed that the end-products of glycolysis, lactate and 
pyruvate, regulate HIF-1 gene expression independently of hypoxia by stimulating 
the accumulation of HIF-1, and thereby facilitating further glycolysis and tumor 
progression in a positive feedback loop [37].  
Also, reactive oxygen species (ROS), or free radicals, are a by-product of cellular 
metabolism [38]. Oxidative stress, a result from imbalance between production of 
ROS and activation of the cell’s own antioxidant defence, is a phenomenon linked to 
carcinogenesis and several other chronic diseases [39]. In excess, ROS can cause 
lipid peroxidation, damage cell membranes, cause DNA damage and lead to cell 
death [38].  
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1.3.4 Hypoxia and Metastasis 
Increased metastatic ability has been associated with hypoxic tumors [40, 41]. 
Evidence show that the effect of hypoxia on malignant progression is mediated by a 
series of hypoxia-induced changes activating angiogenesis, glycolysis and  inhibition 
of apoptosis, in addition to up-regulating growth factors and proteins involved in 
tumor invasiveness [42]. All these features enable tumor cells to survive or escape 
their hostile environment.  
A key step in tumor metastasis is postulated to involve the de-regulation of tumor 
cell-cell and cell-ECM interactions through Epithelial-to-Mesenchymal transition 
(EMT) [26]. EMT is a fundamental process that governs morphogenesis in 
multicellular organisms [43]. However, in tumor progression, EMT is believed to 
have a more sinister role, leading to carcinomas with an invasive or metastatic 
phenotype (Figure 3) [43-45]. Hypoxia has been shown to trigger EMT, enabling cell 
detachment and invasion [46]. The “cadherin switch”, with down-regulation of E-
cadherin (CDH1) and up-regulation of N-cadherin (CDH2) is one of the key 
regulators of EMT, as increased levels of CDH2 increase the motility and migration 
of the cells. Due to the morphological similarities of the primary tumors and the 
metastatic lesions, it has been hypothesized that tumors reactivate certain epithelial 
properties at the secondary site, through a Mesenchymal-to-Epithelial transition 
(MET) [45, 47]. However, this has yet to be proven. Tsuji et al. [48] have proposed 
an alternative hypothesis, where epithelial and mesenchymal cells cooperate to 
induce metastasis, and thus eliminates the need for MET at the distant site. 
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Figure 3: Proposed role of Epithelial-Mesenchymal-transition (EMT) and Mesenchymal-to-
Epithelial-transition (MET) in cancer progression. Local proliferation and transformation of 
epithelial cells can lead to a carcinoma in situ. Further progression – possibly through EMT 
and fragmentation of the basement membrane - can lead to invasion into the lymph or blood 
vessels, and spread to distant organs. At secondary sites, carcinoma cells can extravasate 
and form solitary micrometastasis or form new carcinomas through MET. Adapted from 
Thiery et al. [43], with permission from Nature Publishing Group. 
1.3.5 Hypoxia and Resistance to Therapy 
Hypoxia can be a direct cause of resistance to conventional therapy. Grey et al. [22] 
proved in the 1950ies that oxygen concentration influence the effect of radiation 
therapy. Later, a number of factors associated with tumor hypoxia have also been 
directly or indirectly shown to influence the effect of chemotherapy [49]. The 
hypoxic therapy resistance has been ascribed to: 1) Some drugs and radiation 
requiring oxygen to generate ROS to be maximally cytotoxic. 2) Altered cellular 
metabolism reducing drug cytotoxicity. 3) Hypoxia leading to genetic instability, 
which can lead to more rapid development of drug-resistant cells [50]. Additionally, 
as for oxygen, the distribution of the chemotherapeutic drug is compromised due to 
the uneven blood flow in tumors and high distance from the nearest capillary [51]. 
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1.4 Hyperbaric Oxygen Therapy 
With our present knowledge of hypoxia and its effect on tumor growth, progression 
and response to chemotherapy, we aimed to investigate if a reduction in the hypoxic 
state of the mammary tumors, by enhancing tumor oxygenation, might have an 
inhibitory effect on tumor growth per se, in addition to enhancing the effect of 
chemotherapy. 
Hyperbaric oxygen (HBO) is one way to increase tissue oxygenation. HBO therapy 
involves breathing of 100% oxygen pressurized to 2-3 times atmospheric pressure, 
equivalent to 10-20 meters sea water (msw). By taking advantage of the physical 
properties of gases under pressure, HBO expose tissues to elevated oxygen 
concentrations.   
Henry`s law (Formula 3) states that the amount of a gas that will dissolve in a liquid 
at a given temperature is directly proportional to the partial pressure of the gas above 
the liquid, and of the solubility coefficient of the gas in the liquid. The solubility 
coefficient decreases with rising temperature and increasing salinity.  
 
PC 
  
Formula 3: Henry`s law 
C=The concentration of the solute gas, = The solubility coefficient,  
P= The partial pressure of the gas in the gas phase above the solution. 
 
 
Boyle`s law (Formula 4) states that if the temperature of a fixed mass of gas is kept 
constant, the relationship between volume and pressure will vary in such way that the 
product of the pressure and volume will remain constant.  
       KVP 

Formula 4: Boyle`s law
P= The absolute pressure, V= The volume, K= A constant 
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Together, Boyle`s and Henry`s laws constitute the basis for hyperbaric oxygen 
therapy.  
Increasing the partial pressure of oxygen (pO2) has essentially no effect on the 
amount of oxygen bound to hemoglobin (Hb), as Hb is 96-98 % saturated at sea level 
in normal air, giving a O2 content of approximately 200ml O2/1000mL arterial blood. 
Additionally, 3.2 mL O2/1000mL blood is dissolved in plasma and is carried in 
solution. The saturation/desaturation of dissolved O2 strictly follows Henry`s law 
(Formula 3), while the O2 saturation/desaturation of Hb is modified by the actual pH, 
CO2, 2,3-diphosphoglycerate (2,3-DPG) and temperature, following a sigmoid curve. 
Therefore, treatment with HBO will hyper-saturate the blood with oxygen, as shown 
in Table 1.  
 
Table 1: Theoretical arterial oxygen tensions pO2 (mmHg) and dissolved O2 concentrations 
for different normobaric and hyperbaric oxygen treatment protocols. All values assume 
arterial pO2=alveolar O2. Modified from Tarun et al. [52]. 
Depth Pressure  %O2 pO2 (mmHg) mL dissolved 
O2/1000mL blood 
0 m 1 bar Normal air (~21%) 159 3.2 
0 m 1 bar 100 % 760 20.9 
10 m 2 bar Normal air 318 8.1 
10m 2 bar 100% 1520 44.4 
15m 2.5 bar Normal air 397.5 10.6 
15m 2.5 bar 100% 1900 56.2 
20m 3 bar Normal air 477 13.1 
20 m 3 bar 100 % 2280 68 
 
Thus, at 3 bar pure oxygen, the amount of oxygen dissolved in the blood and 
delivered to the tissues is 20 times higher than during normal atmosphere, and is 
thereby sufficient to support resting tissue without the contribution of hemoglobin 
[53]. The dissolved oxygen can more easily reach areas where the red blood cells 
cannot pass, and can enable tissue oxygenation even with impaired hemoglobin 
oxygen carriage [53]. It has been shown that the distance that oxygen can diffuse 
through normal tissue is increased fourfold after a HBO treatment [54]. Thus, HBO 
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leads to increased oxygenation of tissue by increasing the transport of soluble 
oxygen. In general, if pressure does not exceed 3 bar and the length of therapy is less 
than 2 hours, HBO is considered safe [55]. 
The Undersea and Hyperbaric Medical Society (UHMS) has a list of approved 
indications for HBO-therapy (Table 2). HBO is the treatment of choice for 
decompression sickness, problem wounds and severe carbon monoxide poisoning. 
The duration of a single treatment (2.5-3 bar) varies from 45-90 min for carbon 
monoxide poisoning up to 2-4 h for some severe decompression disorders. For 
problem wounds most protocols average 90-120 min each of 20-30 treatments at 2.4 
bar [56].  
 
Table 2: Approved uses of hyperbaric oxygen (HBO) therapy as defined by the Undersea 
and Hyperbaric Medical Society (UHMS). 
Air or gas embolism 
Carbon monoxide poisoning 
Central retinal artery occlusion 
Clostridal myositis and myonecrosis 
Crush injury, compartment syndrome and other acute traumatic ischemias 
Decompression sickness 
Enhancement of healing in selected problem wounds 
Exceptional blood loss 
Intracranial abscess 
Necrotizing soft tissue infections 
Osteomyelitis 
Delayed radiation injury 
Skin grafts and flaps 
Thermal burns 
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1.5 History of HBO and Cancer 
As in normal tissue, the pO2 in tumor tissue increases significally during HBO 
exposure [57]. It has also been shown that the elevation of the tumor oxygen 
concentration is preserved for more than 60 min after HBO treatment [58].  
The use of HBO in cancer management was controversial, and many had concerns 
that HBO would recruit hypoxic tumor cells into the pool of proliferative cells, 
initiate angiogenesis, and thereby lead to cancer progression. However, two extensive 
reviews have concluded that HBO do not promote tumor growth [59, 60]. To 
complement the reviews written by Daruwalla et al. [60] and Feldmeier et al. [59], I 
have reviewed the work performed on HBO and cancer the last 7 years (Table 4, 
Appendix). This mini-review support the previous findings [59, 60], as  none of the 
reports observed a tumor-promoting effect of HBO (Table 4, Appendix). 
Nevertheless, as other treatment modalities, HBO display great variance in response 
between different tumor types.  
Our group have tested the use of HBO treatment in both mammary tumors and 
gliomas per se, and found that HBO has a significant growth-inhibitory effect in both 
tumor models [61-63]. Thus, these studies formed the background for this thesis.
Stuhr et al. [61] found that HBO both alone and in combination with the 
chemotherapeutic agent 5-fluorouracil (5FU) induced a clear reduction in tumor size 
compared to day 1 measurements in a chemically-induced (DMBA) mammary tumor 
model (Figure 4). The same study also included a group of rats exposed for a longer 
experimental period and with additional treatments (23 days, 7 treatments) [61]. The 
results showed that although the experimental period was prolonged with 12 days and 
three additional HBO treatments, no further reduction in tumor size was registered 
(Figure 5, series 6). Thus, the HBO effect was maximal after four HBO exposures. 
Furthermore, one series followed tumor growth 12 days post HBO treatment (Figure 
5, series 5). This group showed that although HBO treatment was ended, the tumor 
size was significantly below day 1 level. This seems to imply that some permanent 
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changes must have occurred in the tumor tissue and that these changes prevent the 
tumor from further growth.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The effect of 5-fluorouracil (5FU) and hyperbaric oxygen (HBO) on DMBA-
induced tumor growth - alone or in combination. Treatments are given day 1, 4, 7 and 10. 
Values represent means ± SE.  *p<0.05 and **p<0.01. Adapted from Stuhr et al. [61]. 
 
 
 
 
 
 
 
Figure 5: The effect of hyperbaric oxygen (HBO) on DMBA-induced tumor growth. The 
after-effect of 4 HBO exposures (Series 5) and the effect of multiple HBO exposures (Series 
6). Dashed line indicates the level for initial tumor size. * p<0.05 vs day 1 and **p<0.01 vs 
day 1. Adapted from Stuhr et al. [61]. 
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These results support the fact that HBO has a tumor-inhibitory effect on DMBA-
induced mammary tumors per se. The possible use of HBO has a stand-alone- or 
adjuvant treatment in breast cancers is discussed in section 5.1 and 5.2.  
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2. Aims of Study 
The overall aim of this thesis was to study the effect of enhanced oxygenation on 
mammary tumor growth, progression and response to therapy. 
Specific aims 
1) To investigate the effect of HBO therapy on tumor growth and progression in 
two different in vivo mammary tumor models, by elucidating cell proliferation, 
cell death and angiogenesis.  
2) To study the gene expression profile of both untreated and HBO treated 
mammary tumors. 
3) To develop a mammary tumor model, to be able to study tumor-stroma 
interactions, in addition to studying both aim 1 and 2. 
4) To elucidate the effect of HBO on the uptake of a conventional 
chemotherapeutic drug, 5FU, into the mammary tumor tissue. Furthermore, to 
study possible oxygen-related changes occurring in the tumor stroma that 
might have influenced the chemotherapeutic response, as interstitial fluid 
pressure, amount of collagen, fluid distribution and reactive oxygen species.  
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3. Summary of Results 
3.1 Paper I 
Hyperoxic treatment induces Mesenchymal-to-Epithelial Transition in a rat 
adenocarcinoma model. 
Tumor growth in the DMBA-induced tumor model was significantly reduced (~16% 
compared to day 1 levels) on day 11 after HBO treatment (2 bar, pO2 = 2 bar, 4 
exposures à 90 min), whereas control tumors increased almost 100 % in volume 
during the same experimental period. Significant decreases in tumor cell 
proliferation, tumor blood vessels and collagen fibrils, together with an increase in 
cell death, are consistent with tumor growth reduction and tumor stroma influence 
after HBO treatment. Gene expression profiling showed that HBO induced a 
mesenchymal-to-epithelial transition (MET) with coordinated expression of gene 
modules involved in cell junctions and attachments together with a shift towards non-
tumorigenic metabolism.  
3.2 Paper II 
Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors 
independently of changes in interstitial fluid pressure and tumor stroma. 
Uptake of [H3]-5-fluorouracil in the DMBA-induced tumors were increased with 
more than 50% immediately after a single HBO treatment (2 bar, pO2 = 2 bar, 1 
exposure of 90 min). However, this effect was not found when measured 24 hours 
after the last repeated HBO treatment (2 bar, pO2 = 2 bar, 4 exposures à 90 min). 
Tumor interstitial fluid pressure (Pif), lymphatic structures and collagen content 
decreased significantly after HBO. However, HBO did not induce any change in 
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oxygen stress (measured as malondialdehyde levels) and transcapillary transport in 
the tumors. 
3.3 Paper III 
Tumor-stroma interactions in 4T1 mammary tumors with and without 
enhanced oxygenation. 
A new tumor model with dsRed expressing 4T1 mammary tumors in eGFP 
(enhanced green fluorescent protein) expressing NOD/SCID (Non-obese diabetic/ 
Severe combined immunodeficiency) mice was successfully established. 
Fluorescence microscopy, confirmed a successful separation of the tumor- and 
stromal cells after Fluorescence Activated Cell Sorting. Gene expression profiling 
demonstrated that highly up-regulated genes in the untreated tumor stroma included 
constituents of the extracellular matrix and matrix metalloproteinases. Furthermore, 
tumor growth was significantly inhibited by HBO. However, it did not inhibit 
metastasis over time. Immunohistochemistry and gene expression data showed a 
significant anti-angiogenic effect after intermittent HBO (2.5bar, 100% O2, 3 
exposures à 90 min), whilst daily HBO (2.5bar, 100% O2, 7 exposures à 90 min) did 
not show the same response. Neither morphology, proliferation nor the amount of cell 
death was significantly changed after HBO. 
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4. Methodological Considerations 
Detailed descriptions of methods are provided in the respective papers included in 
this thesis. However, aspects influencing choice of animal models and treatment, 
together with their advantages and limitations, are discussed in this section. 
4.1 Animal Models 
We used two different mammary tumor models in this thesis. The first two papers 
were performed on chemically-induced (DMBA) tumors in rats. In Paper III, 4T1 
mammary tumors in mice were used. 
4.1.1 Chemically-Induced DMBA Adenocarcinomas 
Dr. Charles Brenton Huggins developed the DMBA-induced rat mammary carcinoma 
model in 1961 [64]. The polycyclic aromatic hydrocarbon DMBA functions as a 
immunosuppressor, in addition of being a potent organ-specific carcinogen, most 
commonly inducing skin and mammary tumors in animals [65]. This model is now 
one of the most extensively investigated laboratory animal models mimicking human 
breast cancer. Histopathological and immunohistochemical characterization confirm 
that this is a good model for the changes occurring early in the multistep process of 
mammary gland carcinogenesis [66].  Investigation on UHKBR-01, a cell line 
derived from DMBA-induced rat mammary tumors, revealed that the cells are 
oestrogen- and progesterone-receptor positive, like other established breast cancer 
cell lines such as MDA-MB-231 and MCF7, which both are derived from human 
tumors [65].  Taken together with the fact that the effect of HBO on tumor growth, 
alone and in combination with 5FU, already was tested and proven to work reliably 
in this tumor model [61, 63], made it a natural choice for Paper I and II.
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4.1.2 Murine 4T1 Mammary Carcinomas 
4T1 is one of four cell lines isolated from a spontaneously arising autochthonous 
BALB/cfC3H mammary tumor [67]. Normally, human xenograft models metastasize 
poorly or to unexpected sites in mice. In contrast, murine tumor models often have 
more similar metastatic characteristics to that observed in cancer patients. Thus, 
murine  4T1 cells in mice metastasize to lung, liver, brain and bone through the 
hematogenous route, all sites affected in human breast cancer [68]. In this thesis, 4T1 
cells were implanted in NOD/SCID  mice [69]. This stock of mice has been shown to 
have multiple defects in adaptive and innate immune function, and allow a high 
percentage of tumor take, and thereby represent an advanced model for xeno-
engraftment studies [70]. Further, most of the experiments in Paper III are performed 
on dsRed transfected 4T1 tumor cells injected into eGFP expressing NOD/SCID 
mice. This tumor model enables us to visualize in detail the co-localization of the 
tumor and host cells, in addition to enabling separation of the two compartments 
using FACS (fluorescence activated cell sorting). This gives us the opportunity to 
investigate changes occurring in the tumor cells and the stromal cells separately, and 
thereby having a better chance of finding possible mechanisms involved in the effect 
HBO has on tumors. Niclou et al. [70] showed that the eGFP expressing NOD/SCID 
stock had an immunological profile comparable to the non-transgenic parental line, 
and that we can therefore compare results from the NOD/SCID model with the 
fluorescent stock. Coincident with tumor cell implantation, a 17-estadiol pellet 
(0.18mg/pellet-60 day release) was implanted into the neck of the mice. 4T1 lack 
estrogen receptor  (ER), and is therefore non-responsive to estrogen stimulation of 
growth. Nevertheless, Banka et al.[71] found that estrogen stimulation can affect the 
metastatic capability of 4T1 tumors. Thus, we chose to implant estrogen-pellets to be 
able to investigate tumor metastasis in addition to tumor growth. 
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4.1.3 Change of Animal Model 
As Stuhr et al. [61] and Raa et al. [63] both achieved promising results with HBO on 
the DMBA-induced mammary tumor model in rats, we wished to follow-up these 
studies to thoroughly elucidate how enhanced oxygenation influence tumor 
progression and response to chemotherapy in this model. Thus, both Paper I and II 
include studies on the DMBA-induced tumor model. Furthermore, in Paper III we 
wanted to test the hypothesis of enhanced oxygenation in a different mammary tumor 
model, to see if HBO had a general tumor-inhibitory effect on mammary tumors. 
Development of a mammary tumor model with dsRed 4T1 tumor cells injected in 
eGFP mice, enabled us to separately investigate oxygen-related changes occurring 
both in the tumor cells and in the tumor stroma. As of today, eGFP rats are not 
available, but if so, rats would be preferred, as tumor growth studies in rats enables 
longer experimental periods without influencing with the mobility and welfare of the 
animals, and also provides more tissue for analysis. 
4.2 Hyperbaric Oxygen 
In clinical practice, side effects of HBO are rare and mild because of the relatively 
low oxygen pressures used and the limited time of the treatment sessions.  
4.2.1 Side Effects due to changes in Atmospheric Pressure 
During compression and decompression of the hyperbaric chamber, the pressure-
volume relationship described in Boyles law (Formula 4), may cause unpleasant or 
more serious side effects.  
The most frequent problem caused by changes in atmospheric pressure is middle ear 
barotraumas, due to insufficient equilibration of the middle ear. Further, perforation 
of the oval window, and thereby leakage of perilymph from the inner ear to the 
middle ear, is a rare, but serious side effect. The most serious effect of barotrauma is 
pneumothorax, wherein air or gas is present in the pleural cavity, and leads to 
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collapse of the lung. However, this state has only been reported in a few cases, and 
always in comatose or ventilated patients [54]. Most of the adverse effects of 
hyperbaric conditions are, however, related to rapid decompression, i.e. relieving 
pressure [72]. Normally, gases of the atmosphere are in solution in the body tissues. 
Exposure to increased environmental pressure, leads to increased solubility of these 
gases in the body fluids, until saturation is reached. A sudden decrease of 
environmental pressure will lead to bubble formation. Still, the bubbles are mainly 
caused by nitrogen, as the body quickly can consume and deal with excess oxygen 
and carbon dioxide, and these bubbles induce decompression sickness. 
Decompression sickness can take several forms. Type I, or “the bends”, is related to 
pain in the major joints. Type II is a more serious condition and involves pulmonary, 
cardiac, ophthalmic, or neurological symptoms and the possibility of shock or coma 
[72]. HBO have shown beneficial effects on patients with decompression sickness, by 
reducing the bubble size, increasing the dissolution of the gas bubbles and counteract 
the hypoxic condition [56]. 
In the present study, both compression and decompression of the chamber was 
performed following a conservative schedule, using 3-5 min to reach the desired 
pressure and ~10 min to decompress the animals. The animals did not show any sign 
of discomfort during pressure changes. 
4.2.2 Side Effects due to Oxygen Partial Pressue 
In 1878, Paul Bert was the first to demonstrate the toxicity of oxygen. Thus, seizures 
resulting from acute oxygen toxicity to the central nervous system are still referred to 
as the "Paul Bert effect". Now it is clear that brain oxygen toxicity is pressure 
dependent and the immediate toxicity is reached by breathing 100% oxygen at 4-5 
bar [73]. At lower pressure the threshold is time dependent. Later, Lorrain Smith 
discovered that even moderate oxygen tensions could lead to serious and fatal lung 
injuries when the exposure time was long enough. This chronic pulmonary oxygen 
poisoning is therefore called the “Lorrain Smith effect”. Oxygen lung toxicity is 
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related to the cumulative damage from oxygen free radicals to lung parenchyma and 
airways and may thereby only occur during prolonged hyperbaric treatments [54]. 
Further, symptoms of oxygen toxicity may include disorientation, breathing problems 
and vision changes. Repeated HBO sessions may lead to transient myopia [74], but is 
reversed a few weeks after the cessation of treatment. In any environment with raised 
oxygen pressure, there is an increased risk of fire.  
 
Pott et al. [75] found no persistent effect on pulmonary function after 90 min HBO 
treatment of 2.4 bar. Together with the study by Lambertsen et al. [73], this clearly 
show that the pressure and time-frame used in our experiments are within safe range 
and that neither acute nor chronic oxygen toxicity was considered a problem. 
Furthermore, to avoid the fire hazard in the pure O2 environment, the animals were 
showered lightly with water prior to entering the pressure chamber. Additionally, the 
chamber was litter free, oil free and all electrical connections were disconnected. 
4.2.3 Change of HBO Protocols  
In paper I and II, the animals were treated 4 times for 90 min in a 2 bar and 100% O2 
atmosphere. This protocol was chosen, as these studies were performed as follow-up 
studies of Stuhr et al. [61]. They found that an extended experimental period, with 7 
HBO treatments over 23 days, gave no further reduction in tumor size, and thus 4 
treatments were chosen [61]. Additionally, Paper II included a single HBO treated 
group, to be able to study the acute effect of increased pO2.  
Raa et al. [63]  studied the effect of normobaric- and hyperbaric hyperoxia. This 
study, combined with the study by Stuhr et al. [61] indicate that the growth reduction 
is dose-dependent on pO2. Therefore, in Paper III, the HBO protocol was slightly 
changed. First, the atmospheric pressure was increased to 2.5 bar, to see if increased 
pO2 would induce an even greater growth-inhibitory response. Furthermore, due to 
the change of animal model from rats to mice and the aggressiveness of the 4T1 
tumors, the control mice could not carry the tumors for more than 8 days. Thus, the 
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treatment protocol was reduced from 4 treatments over 11 days, to 3 treatments over 
8 days. Additionally, one group of mice was treated daily with HBO, to elucidate if 
this could possibly potentiate the inhibitory effect of HBO, or if the tumors would 
adapt to the enhanced oxygenation, and thus display less response to the treatment. 
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5. General Discussion  
Although cancer research has made significant progress, important questions within 
this field are still unanswered. Hypoxia is one of the known features of solid tumors, 
and has been connected to several important parameters influencing both tumor 
growth and response to therapy. Thus, the rationale for focusing on tumor 
oxygenation in this thesis, is the hypothesis that hyperoxia, “the flip of the coin”, 
might counteract some of the mentioned negative aspects of hypoxia and thereby lead 
to additional insight into the effects of tumor oxygenation.  
5.1 HBO in Cancer Treatment 
As oxygen is believed to be required for all the major processes of wound healing, 
including resistance to infection, collagen deposition, angiogenesis and epithelisation 
[76], one feared that HBO would have the same proliferative effect in tumors. 
Therefore, throughout the 1950ies and 1960ies, the effect of HBO on cancers was 
tested to elucidate if HBO did promote tumor growth. The results from the studies 
were reviewed by both Feldmeier et al. [59] and Daruwalla et al. [60]. The reviewed 
studies included different types of cancers, with and without additional therapy, and 
thus had a variety of responses. Nevertheless, both reviewers concluded that HBO did 
not promote tumor growth, and that the use of HBO in patients with malignancies 
was considered safe. Subsequently, systematic research on HBO and cancer was 
terminated. It is important to emphasize that an effect of HBO treatment per se on 
tumors possibly depends on multiple factors, including tumor type and stage, as well 
as the timing, duration, atmospheric pressure and number of HBO exposures. In vitro 
studies have shown that there are discrepancies in growth fraction between cell lines 
exposed to hyperoxia [77], indicating differences in response to oxygen between 
different tumor types. This is reflected in the literature where patients with head and 
neck cancers tend to be most responsive to HBO therapy and patients with cervical 
and bladder cancer least responsive [60]. Thus, the observed variety in response to 
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HBO observed by Feldmeier et al. [59] and Daruwalla et al. [60] can therefore be 
ascribed to both differences in types of tumors, but also to the large variety in HBO 
treatment protocols. Nevertheless, studies from our group have demonstrated a 
growth-inhibitory effect of HBO on mammary tumors [61, 63], and therefore 
elucidation of HBO’s effect on mammary tumors were the scope of this thesis. 
Previous studies performed on HBO and cancers have only included evaluation of 
tumor growth and/or metastasis. Hence, the work performed in this thesis have 
looked further into the changes oxygenation causes in the tumor tissue, and 
considered the possibility that HBO might have been too early abandoned as a 
possible cancer treatment, at least as a treatment adjuvant. 
Hyperoxia and the Angiogenic Switch 
Even though clinical experience has shown that hyperoxia stimulate healing of 
wounds, the mechanisms accounting for the dependency of oxygen on angiogenesis, 
are largely unknown [78]. In contrast to the comprehension that oxygen leads to 
angiogenesis and collagen deposition in non-tumor tissue, our work show that HBO 
has an anti-angiogenic effect and leads to less fibrosis in tumors [62, 63, 79, 80]. 
Thus, this thesis contributes to new understanding of oxygen and its influence on 
angiogenesis in tumor tissue. It is well known that the HIF-1-pathway is activated 
during hypoxia. It is therefore paradoxical that increased oxygenation should lead to 
increased angiogenesis in wound healing of non-tumor tissue, as HIF-1 is degraded 
when oxygenated. On the other hand, the anti-angiogenic effect we observed after 
hyperoxia, where several growth factors known to be induced by HIF were 
significantly reduced, supports the fact that HIF-1 is degraded during oxygenation. 
Based on the fact that angiogenesis creates new blood vessels that can nurture the 
tumor tissue, anti-angiogenesis could help explain the tumor-inhibitory effect. 
However, since both daily and intermittent HBO treatment of the 4T1 tumors in 
Paper III induced a growth-inhibitory effect, but only the intermittent group 
displayed anti-angiogenesis, angiogenesis cannot be the main determining factor 
behind the observed growth inhibition. 
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Hyperoxia and Cell Survival 
Together, Papers I and III indicate that HBO has a general tumor-inhibitory effect on 
mammary tumors. However, the extent of tumor-inhibition is far greater in the 
chemically-induced DMBA-tumors than in the 4T1 tumors. This also shows that 
despite the increased atmospheric pressure (from 2 to 2.5 bar); used in treating the 
4T1 tumors, the HBO treatment did not induce a more pronounced tumor-inhibitory 
response. This indicates that the previously observed dose-dependency of pO2 in the 
DMBA tumors [63] is not applicable when changing tumor models. 
Immunohistochemistry revealed differences in response to HBO with respect to both 
cellular proliferation and cell death in the two tumor models. While HBO display an 
anti-proliferative and pro-apoptotic effect in the DMBA-tumors, no significant 
changes in these parameters were observed in the 4T1 model. One might speculate if 
the 4T1 tumor were less hypoxic, and thereby displayed less response to enhanced 
oxygenation.  
Hyperoxia and the Glycolytic Switch 
Lòpez-Làzaro [81] published a review in 2009 questioning the importance of hypoxia 
in tumor progression, and proposed the alternative idea, viewing cancer as a process 
in which oxygen metabolism is altered from an energy-generating pathway to an 
ROS-producing pathway. With this in mind, the results from Paper I indicate a switch 
to a non-tumorigenic metabolism, while this metabolic-switch was not observed in 
the 4T1 tumors in Paper III. This discrepancy in metabolism could be a reasonable 
explanation for the difference in the extent of tumor growth-inhibition in the two 
mammary tumor models. 
Hyperoxia and Metastasis 
Metastasis is the major cause of cancer deaths [40]. As stated in the introduction, 
hypoxia increases the metastatic capability of tumors [40, 41]. In accordance to this, 
results from Paper I indicated that oxygen is an important factor in the “switch” from 
EMT to MET, leading to less aggressive and invasive tumors. On the other hand, the 
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supplementary results in Paper III show that HBO did not seem to inhibit the 
metastatic capability of the 4T1 tumor model over time. Thus, oxygen does not 
induce the same “switch” in all tumor models. Due to the fact that the DMBA tumor 
is not a metastatic model, the influence of MET on the metastatic behaviour is hard to 
determine. However, the significance of O2 as a factor in the induction of MET in 
DMBA-induced tumors is still interesting, since such a transition is believed to 
induce a less aggressive phenotype. 
 
Only a few other experimental studies have elucidated the effect of HBO per se on 
breast cancer growth and metastasis. Granowitz et al. [82] and Chen et al. [83] 
concluded that HBO had a significant inhibitory effect on mammary cell proliferation 
in vitro, which is in accordance with the results from our in vivo models. Further, 
McCredie et al.[84] and Haroon et al. [85]  found that HBO did not promote 
metastatic capability. Nevertheless, even though HBO display tumor-inhibitory 
effects in the mammary tumor models described in this thesis, there are too few 
studies supporting HBO inhibitory effects as a stand-alone mammary cancer therapy. 
However, combining enhanced oxygenation with chemotherapy, or another tumor-
inhibiting modality, may be one way to synergistically improve the treatment effect. 
5.2 HBO as a Chemoterapeutic Adjuvant 
As opposed to studying the effect of HBO per se on tumor growth, several studies 
have elucidated HBO as an adjuvant to conventional chemotherapy, both 
experimentally and in a clinical setting [61, 82, 86-92]. The studies were performed 
on different tumor types, with different chemotherapeutic drugs, and thus with great 
variation in response. Teicher [50] underlines that the importance of hypoxia on the 
response to chemotherapy is highly drug dependent. As stated in the introduction, 
hypoxia-mediated chemo-resistance has been ascribed to: 1) Some drugs and 
radiation requiring oxygen to generate ROS to be maximally cytotoxic. 2) Altered 
 40 
cellular metabolism reducing drug cytotoxicity. 3) Hypoxia leading to genetic 
instability, which can lead to more rapid development of drug-resistant cells [50]. In 
addition the cytotoxicity, availability of the chemotherapeutic drug is important to 
obtain maximal effect. Tumor tissue anatomy influence transport of intravenously 
injected substances to the tumor cells, and thus the efficacy of the drug.  
5FU is a chemotherapeutic drug widely used in treatment of cancers, including 
colorectal cancer and breast cancers [93]. Paper II showed that the uptake of 
radioactively labelled 5FU was increased compared to control immediately after one 
HBO treatment, when the pO2 was still high, but not 24 hours after the last of 4 
repeated treatments. Oxygen-related changes observed in the tumor stroma, like 
collagen density and Pif, did not seem to influence the uptake, as thoroughly 
discussed in Paper II. Rump et al. [94] speculated if hyperbaric or hyperoxic 
conditions may affect the drug distribution by changing the catalytic activity of drug 
metabolizing enzymes, the hemodynamics and membrane permeability. The 
synergistic effect of HBO and 5FU observed by Stuhr et al. [61] is therefore not only 
ascribed to increased cytotoxicity, but seems to be related to increased availability of 
the chemotherapeutic drug, due to increased uptake.  
Pre-clinical studies have shown, that combining HBO with the right 
chemotherapeutic drug, might improve the treatment outcome of several types of 
cancer [61, 82, 88-92, 95]. However, further research within this field is needed to 
elucidate the mechanisms underlying the synergistic effect of oxygen and 
chemotherapy. 
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6. Conclusions
Our overall aim in this thesis was to study the effect of enhanced oxygenation on 
tumor growth, progression and response to therapy. 
We therefore addressed and answered the following specific aims: 
1. To investigate the effect of HBO therapy on tumor growth and 
progression in two different mammary tumor models, by elucidating cell 
proliferation, cell death and angiogenesis.  
HBO significantly inhibited mammary tumor growth in both the chemically-
induced DMBA tumors and the 4T1 tumors. Intermittent/Repeated HBO had a 
significant anti-angiogenic effect in both tumor models. However, while HBO 
had a pro-apoptotic and anti-proliferative effect on the DMBA-tumors, no such 
effect was apparent in the 4T1 tumors. (Paper I and III).  
2. To study the gene expression profile of both untreated and HBO treated 
tumors. 
Gene expression profiling showed that HBO induced a Mesenchymal-to-
Epithelial Transition and a shift towards a non-tumorigenic metabolism in the 
DMBA-induced mammary tumors, leading to more differentiated and less 
aggressive tumor phenotype. No such transition was observed in the 4T1 
tumors. Additionally, the immunohistochemical findings on angiogenesis, cell 
proliferation and cell death were supported by results from the gene expression 
analysis (Paper I and III). 
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3. To develop a mammary tumor model, to be able to study both aim 1 and 
2, in addition to elucidate tumor-stroma interactions. 
A new mammary tumor model was established, with dsRed transfected 4T1 
tumor cells injected into eGFP expressing NOD/SCID mice. This mammary 
tumor model enabled us to separate tumor and stromal cells, and demonstrated 
that the two compartments are characterized by distinct gene expressions, both 
in the native state and following HBO treatments (Paper III).  
4. To elucidate the effect of HBO on the uptake of a conventional 
chemotherapeutic drug, 5FU, into the tumor tissue,  and study possible 
oxygen-related changes occurring in the tumor stroma that might have 
influenced the chemotherapeutic response, as interstitial fluid pressure, 
amount of collagen, fluid distribution and reactive oxygen species.  
HBO increased the uptake of [H3]-5FU in the DMBA induced mammary 
tumors per se, independently of changes in Pif, oxygen stress, collagen fibril 
density or transendothelial transport alone (Paper II).  
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7. Future Perspectives and Concluding Remarks
Paper I, II and II have taken us one step closer to determining the effect of enhanced 
oxygenation on mammary tumor growth, progression and response to therapy by 
elucidating changes occurring in the tumor tissue.  
Due to the observed tumor-inhibitory effect of HBO on both the DMBA- induced- 
and the 4T1 mammary tumors, we aim to study a human mammary tumor model, 
MDA-231, in vivo. By elucidating the response to this human tumor model, we wish 
to increase the clinical relevance of the studies and get an even closer look into the 
background for the response to HBO.  
To be able to reach our ultimate goal of finding the mechanisms by which oxygen 
influence tumor development and response to therapy, further in vitro studies have 
been outlined. We aim to study cell proliferation of the breast cancer lines, 4T1, 
MDA-MB-231 and MCF-7 in vitro, after exposing the cells to three different oxygen-
environments, hypoxia (2% O2), normoxia (20% O2) and hyperoxia (80% O2). After 
incubation of the cells in the different oxygen-concentrations, gene expression studies 
will hopefully help us uncover possible oxygen-sensitive genes involved in tumor 
growth and progression.  Thus, by comparing genes that respond in opposite direction 
after hypoxic and hyperoxic conditions, we can possibly indentify important oxygen-
dependent genes for further evaluation.  
Ultimately, we wish to study Lentiviral/siRNA over-expression and knock-out 
strategies of the possible oxygen-dependent genes. This will first be performed on 
cell lines, before prospective functional validation in vivo.  
In turn, this may provide important new information as to how growth of cancers 
might be controlled, to potentially provide new treatment strategies for both breast 
cancer, but also other types of neoplasms.  
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Errata 
Introduction: 
1.3, line 12, Michieli et al. should read Michieli. 
1.3.5, line 1, Grey et al. should read Gray et al. 
Paper I:  
Table 3, Agilent Human Whole Genome Oligo Microarrays should read Agilent 
G413F Whole Rat Genome (4x44k) Oligo Microarray Kit. 
Figure 3C, should not contain heading (Number of collagen fibrils (2C)). 
Paper III: 
Discussion, page 13, paragraph 3, line 3, fgf should read FGF. 
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Appendix 
Table 3: Pressure conversion table. 
            To     
From 
atm bar kPa msw 
atm 1 1.013 101.325 10.123 
bar 0.987 1 100 10 
kPa 9.869 x 10-3 0.010 1 0.1 
msw 0.099 0.1 10 1 
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el
ia
, 
pr
im
ar
y 
tu
m
or
 a
nd
 m
et
as
ta
tic
 tu
m
or
 
+ 
hu
m
an
 M
C
F7
 c
el
l l
in
e.
  
2.
4 
at
m
 
M
el
ph
al
an
, 
G
em
ci
ta
bi
ne
 
an
d 
Pa
cl
ita
ce
l. 
H
B
O
 in
hi
bi
ts
 c
el
l p
ro
lif
er
at
io
n 
al
on
e,
 
an
d 
au
gm
en
te
d 
th
e 
ef
fe
ct
 o
f 
al
l t
hr
ee
 
ch
em
ot
he
ra
pe
ut
ic
 a
ge
nt
s. 
 
H
ey
s 
et
 a
l. 
[8
7]
 
20
06
 
C
lin
ic
al
 
Lo
ca
lly
 
ad
va
nc
ed
 
br
ea
st
 
ca
rc
in
om
a.
 
2.
4/
2.
0 
at
m
, 
da
ily
 
ex
p.
 fo
r 1
0 
da
ys
. 
C
yc
lo
-
ph
os
ph
am
id
e
,D
ox
or
ub
ic
in
,V
in
cr
is
tin
e.
 
H
B
O
 l
ea
d 
to
 r
ed
uc
ed
 o
ed
em
a,
 b
ut
 
sh
ow
ed
 
no
 
re
du
ct
io
n 
in
 
tu
m
or
 
vo
lu
m
e 
or
 in
cr
ea
se
 in
 v
as
cu
la
ris
at
io
n.

 
D
ar
uw
al
la
 
et
 a
l. 
[1
00
] 
20
06
 
In
 v
iv
o 
D
im
et
hy
l h
yd
ra
zi
ne
 (D
M
H
) 
in
du
ce
d 
pr
im
ar
y 
co
lo
n 
ca
rc
in
om
a 
ce
ll 
lin
e 
in
 m
ic
e.
 
2.
4 
at
m
, 9
0 
m
in
 d
ai
ly
 
ex
p.
 fo
r 7
, 1
3,
 1
9 
an
d 
25
 d
ay
s. 
 
H
B
O
 c
au
se
d 
no
 r
ed
uc
tio
n 
in
 l
iv
er
 
m
et
as
ta
si
s. 
H
B
O
-tr
ea
te
d 
tu
m
or
s 
w
er
e 
ge
ne
ra
lly
 sm
al
le
r t
ha
n 
th
e 
co
nt
ro
ls
. 

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St
ud
y 
Y
ea
r 
T
yp
e 
of
 
st
ud
y 
T
um
or
 ty
pe
 
H
B
O
 p
ro
to
co
l 
A
dd
iti
on
al
 
th
er
ap
y 
C
om
m
en
t 
O
ut
co
m
e 
D
ar
uw
al
la
 
et
 a
l. 
[1
01
] 
20
07
 
In
 v
iv
o 
Pr
im
ar
y 
co
lo
n 
ca
rc
in
om
a 
ce
ll 
lin
e 
in
 m
ic
e.
 
2.
4 
at
m
, 5
 ti
m
es
 à
 9
0 
m
in
 o
ve
r 9
 d
ay
s. 
SM
A
-
pi
ra
ru
bi
ci
n 
H
B
O
 t
he
ra
py
 a
lo
ne
 g
av
e 
no
 e
ff
ec
ts
, 
ho
w
ev
er
 i
n 
co
m
bi
na
tio
n 
w
ith
 S
M
A
-
pi
ra
ru
bi
ci
n 
H
B
O
 g
av
e 
re
du
ct
io
n 
in
 
bo
th
 
liv
er
 
m
et
as
ta
si
s 
an
d 
tu
m
or
 
gr
ow
th
, a
nd
 s
ho
w
ed
 in
cr
ea
se
d 
le
ve
ls
 
of
 n
ec
ro
si
s. 
 
R
aa
 
et
 
al
. 
[6
3]
 
20
07
 
In
 v
iv
o 
D
M
B
A
-in
du
ce
d 
m
am
m
ar
y 
tu
m
or
s i
n 
ra
ts
 
H
yp
er
ox
ia
 
(1
00
%
 
O
2) 
or
 1
.5
 b
ar
, 4
 e
xp
. 
à 
90
 
m
in
 
ov
er
 
11
 
da
ys
. 
5F
U
 
B
ot
h 
hy
pe
ro
xi
a 
an
d 
H
B
O
 i
nd
uc
ed
 
tu
m
or
 g
ro
w
th
 re
ta
rd
at
io
n,
 in
 a
dd
iti
on
 
to
 
re
du
ci
ng
 
va
sc
ul
ar
 
de
ns
ity
 
an
d 
en
ha
nc
in
g 
ce
ll 
de
at
h.
 
 
H
ar
oo
n 
et
al
. [
85
] 
20
07
 
In
 v
iv
o 
M
ou
se
 
m
am
m
ar
y 
ad
en
oc
ar
ci
no
m
a 
4T
1-
G
FP
 
ce
ll 
lin
e 
in
 n
u/
nu
 m
ic
e.
 
2.
8 
A
TA
 f
or
 4
5 
m
in
 
da
ily
 (
5/
 w
ee
k)
 u
p 
to
 
5 
w
ee
ks
. 
 
Th
e 
to
ta
l m
et
as
ta
tic
 lo
ad
 w
as
 re
du
ce
d 
af
te
r H
B
O
 tr
ea
tm
en
t. 
 
St
uh
r 
et
 a
l. 
[6
2]
 
20
07
 
In
 v
iv
o 
B
T4
C
 ra
t g
lio
m
a 
xe
no
gr
af
ts
 
in
 n
ud
e 
ra
ts
. 
10
0%
 O
2 
or
 2
 b
ar
 
H
B
O
, 
3 
ex
p.
 
à 
90
 
m
in
 o
ve
r 8
 d
ay
s. 
 
N
or
m
ob
ar
ic
 
an
d 
hy
pe
rb
ar
ic
 
hy
pe
ro
xi
a 
in
hi
bi
te
d 
tu
m
or
 
gr
ow
th
, 
in
du
ce
d 
ce
ll 
de
at
h 
an
d 
re
du
ce
d 
th
e 
va
sc
ul
ar
 d
en
si
ty
. 
 
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St
ud
y 
Y
ea
r 
T
yp
e 
of
 
st
ud
y 
T
um
or
 ty
pe
 
H
B
O
 p
ro
to
co
l 
A
dd
iti
on
al
 
th
er
ap
y 
C
om
m
en
t 
O
ut
co
m
e 
 C
he
n 
et
 a
l. 
[8
3]
 
20
07
 
In
 v
itr
o 
H
um
an
 l
eu
ke
m
ia
 (
Ju
rk
at
), 
m
ul
tip
le
 
m
ye
lo
m
a 
(N
C
l-
H
92
9)
, 
ca
rc
in
om
a 
(A
54
9)
 
an
d 
br
ea
st
 a
de
no
ca
rc
in
om
a 
(M
C
F-
7)
 c
el
l l
in
es
. 
2.
5 
or
 
3.
5 
A
TA
 
ox
yg
en
 o
r 
ai
r 
fo
r 
2-
12
 h
. 
 
H
B
O
 
in
du
ce
d 
ap
op
to
si
s 
in
 
th
e 
he
m
ap
oi
et
ic
 
Ju
rk
at
 
an
d 
N
C
l-H
92
9 
ce
lls
, b
ut
 n
ot
 in
 A
54
9 
or
 M
C
F7
 c
el
ls
. 
H
B
O
 
di
d 
al
so
 
in
hi
bi
t 
ce
ll 
pr
ol
ife
ra
tio
n 
in
 th
e 
M
C
F7
 c
el
ls
. 
/

 
Sc
hö
nm
ey
r 
et
 a
l. 
[1
02
] 
20
08
 
In
 
vi
tr
o 
an
d 
in
 
vi
vo
M
ur
in
e 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a 
(S
C
C
-V
II
) 
ce
ll 
lin
e 
in
 v
itr
o 
an
d 
in
 m
ic
e.
 
2.
1a
tm
 8
 d
ai
ly
 e
xp
. à
 
90
 m
in
. 
 
H
B
O
 d
oe
s 
no
t 
al
te
r 
ce
ll 
gr
ow
th
 a
nd
 
pr
ol
ife
ra
tio
n 
ne
ith
er
 i
n 
vi
vo
 n
or
 i
n
vi
tr
o.
 

 
O
hg
ur
i 
et
al
. [
86
] 
20
09
 
C
lin
ic
al
 
Pa
tie
nt
s 
w
ith
 n
on
-s
m
al
l-c
el
l 
lu
ng
 c
an
ce
r (
N
SC
LC
). 
W
ee
kl
y 
ch
em
ot
he
ra
py
 
an
d 
hy
pe
rth
er
m
ia
 
w
as
 
ad
m
. 
im
m
ed
ia
te
ly
 
af
te
r H
B
O
. 
Pa
cl
ita
xe
l 
an
d 
ca
rb
op
la
tin
.  
75
%
 o
f 
pa
tie
nt
s 
w
ith
 H
B
O
 h
ad
 a
n 
ob
je
ct
iv
e 
re
sp
on
se
. 
H
yp
er
th
er
m
ia
 
an
d 
H
B
O
 m
ay
 b
e 
a 
fe
as
ib
le
 a
nd
 
pr
om
is
in
g 
m
od
al
ity
 
fo
r 
tre
at
in
g 
N
SC
LC
. 

/
 
Su
zu
ki
 
et
al
. [
88
] 
20
09
 
C
lin
ic
al
 
Pa
tie
nt
s 
w
ith
 
re
cu
rr
en
t 
m
al
ig
na
nt
 
or
 
br
ai
ns
te
m
 
gl
io
m
as
. 
0.
2M
Pa
, 
60
 
m
in
 
du
rin
g 
i.v
. 
ad
m
. 
of
 
ca
rb
op
la
tin
 
+ 
24
 
h 
af
te
r d
ru
g 
ad
m
.  
C
ar
bo
pl
at
in
. 
Th
e 
re
su
lts
 s
ug
ge
st
 th
at
 H
B
O
 th
er
ap
y 
pr
ol
on
gs
 
th
e 
bi
ol
og
ic
al
 
re
si
de
nc
e 
tim
e 
of
 c
ar
bo
pl
at
in
. 
 
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St
ud
y 
Y
ea
r 
T
yp
e 
of
 
st
ud
y 
T
um
or
 ty
pe
 
H
B
O
 p
ro
to
co
l 
A
dd
iti
on
al
 
th
er
ap
y 
C
om
m
en
t 
O
ut
co
m
e 
K
aw
as
oe
 e
t
al
. [
89
] 
20
09
 
In
 
vi
tr
o 
an
d 
in
 
vi
vo
.
M
ou
se
 
os
te
os
ar
co
m
a 
(L
M
8)
 c
el
l l
in
e 
in
 v
itr
o 
an
d 
im
pl
an
te
d 
in
 m
ic
e.
 
2.
5 
at
m
 fo
r 9
0 
m
in
. 
C
ar
bo
pl
at
in
. 
H
B
O
 
m
ar
ke
dl
y 
su
pp
re
ss
ed
 
th
e 
gr
ow
th
 a
nd
 m
et
as
ta
si
s 
bo
th
 i
n 
vi
tro
 
an
d 
in
 v
iv
o.
 H
B
O
 a
ls
o 
re
in
fo
rc
ed
 th
e 
ef
fe
ct
 o
f c
ar
bo
pl
at
in
.  
 
M
oe
n 
et
 a
l. 
[7
9]
 
20
09
 
In
 v
iv
o 
D
M
B
A
-in
du
ce
d 
m
am
m
ar
y 
tu
m
or
s i
n 
ra
ts
. 
2.
0 
ba
r, 
4 
ex
p.
 
à 
90
m
in
, 1
1 
da
ys
. 
 
H
B
O
 i
nh
ib
ite
d 
tu
m
or
 g
ro
w
th
, 
an
d 
sh
ow
ed
 
an
ti-
an
gi
og
en
ic
, 
an
ti-
pr
ol
ife
ra
tiv
e 
an
d 
pr
o-
ap
op
to
tic
 e
ff
ec
t, 
an
d 
m
or
e 
di
ff
er
en
tia
te
d 
an
d 
le
ss
 
ag
gr
es
si
ve
 tu
m
or
s. 
 
 
M
oe
n 
et
 a
l. 
[8
0]
 
20
09
 
In
 v
iv
o 
D
M
B
A
-in
du
ce
d 
m
am
m
ar
y 
tu
m
or
s i
n 
ra
ts
. 
2.
0 
ba
r, 
4 
ex
p.
 
à 
90
m
in
 o
ve
r 
11
 d
ay
s 
or
 1
 e
xp
. à
 9
0 
m
in
. 
5F
U
 
H
B
O
 i
nc
re
as
ed
 t
he
 u
pt
ak
e 
of
 [
H
3 ]-
5F
U
 p
er
 se
. 
 
Ta
ng
 e
t 
al
. 
[1
03
] 
20
09
 
In
 v
iv
o 
H
um
an
 p
ro
st
at
e 
PC
-3
 c
el
ls
 
in
 im
m
un
od
ef
ic
ie
nt
 m
ic
e.
 
2a
tm
, 
20
 e
xp
. 
à 
90
 
m
in
, 
5 
da
ys
 a
 w
ee
k 
fo
r 4
 w
ee
ks
. 
 
H
B
O
 
di
d 
no
t 
ha
ve
 
an
y 
tu
m
or
 
st
im
ul
at
or
y 
ef
fe
ct
s. 
 

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St
ud
y 
Y
ea
r 
T
yp
e 
of
 
st
ud
y 
T
um
or
 ty
pe
 
H
B
O
 p
ro
to
co
l 
A
dd
iti
on
al
 
th
er
ap
y 
C
om
m
en
t 
O
ut
co
m
e 
Se
lv
en
di
ra
n 
et
 a
l. 
[1
04
] 
20
10
 
In
 v
iv
o 
H
um
an
 
ov
ar
ia
n 
ca
nc
er
 
xe
no
gr
af
t. 
2 
at
m
, 
90
 m
in
 d
ai
ly
 
fo
r u
p 
to
 2
1 
da
ys
. 
C
is
pl
at
in
 
H
B
O
 in
du
ce
d 
a 
si
gn
ifi
ca
nt
 r
ed
uc
tio
n 
in
 t
um
or
 v
ol
um
e,
 b
ot
h 
al
on
e 
an
d 
in
 
co
m
bi
na
tio
n 
w
ith
 c
is
pl
at
in
. 
 
O
hg
am
i 
et
al
. [
10
5]
 
20
10
 
In
 v
itr
o 
M
ol
t-4
 
hu
m
an
 
le
uk
em
ia
 
ce
lls
. 
3.
5 
at
m
, 9
0 
m
in
. 
A
rte
m
is
in
in
 
C
om
bi
ne
d 
ar
te
m
is
in
in
 
an
d 
H
B
O
 
de
cr
ea
se
d 
ce
ll 
gr
ow
th
. 
 
Pe
ng
 e
t 
al
. 
[9
1]
 
20
10
 
In
 v
itr
o 
N
as
op
ha
ry
ng
ea
l 
ca
rc
in
om
a 
C
N
E2
Z 
ce
lls
. 
2 
A
TA
, 
85
%
 
O
2,
 
ex
p.
 
à 
90
 
m
in
 
re
pe
at
ed
 
at
 
a 
4 
h 
in
te
rv
al
. 
5F
U
 
H
B
O
 
tre
at
m
en
t 
in
hi
bi
te
d 
pr
ol
ife
ra
tio
n,
 b
ut
 n
ot
 m
et
as
ta
si
s. 
A
 
sy
ne
rg
is
tic
 
ef
fe
ct
 
in
 
co
m
bi
na
tio
n 
w
ith
 5
FU
 w
as
 o
nl
y 
ob
se
rv
ed
 a
fte
r 4
8 
h.
 
/

 
 

